Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -24.34% is 99% below its 5-year average of -12.22%, around the middle of its 5-year range (-201.39%–247.63%).
45.79% above its 12-month average of -44.90%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.63%.
RETURN ON ASSETS (ROA)
-24.34%
RETURN ON ASSETS (ROA) AVG TTM
-44.90%
RETURN ON ASSETS (ROA) AVG 3Y
-10.89%
RETURN ON ASSETS (ROA) AVG 5Y
-12.22%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.79%
CURRENT VS 3Y AVG
-123.51%
CURRENT VS 5Y AVG
-99.10%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.84%
median of 768 covered companies
CURRENT VS SECTOR MEDIAN
+21.09%
vs the sector median at left
Palvella Therapeutics, Inc.
Market Cap
$1.85B
Return on Assets (ROA)
-24.34%
TTM Avg
-44.90%
3Y Avg
-10.89%
5Y Avg
-12.22%
Market Cap
$1.86B
Return on Assets (ROA)
1.78%
TTM Avg
2.10%
3Y Avg
3.84%
5Y Avg
3.40%
Market Cap
$1.84B
Return on Assets (ROA)
-25.92%
TTM Avg
12.70%
3Y Avg
-8.51%
5Y Avg
-21.36%
Market Cap
$1.84B
Return on Assets (ROA)
-6.55%
TTM Avg
-5.28%
3Y Avg
-5.65%
5Y Avg
-2.06%
Market Cap
$1.82B
Return on Assets (ROA)
-4.29%
TTM Avg
-7.68%
3Y Avg
-13.57%
5Y Avg
-14.36%
Market Cap
$1.89B
Return on Assets (ROA)
11.27%
TTM Avg
-4.02%
3Y Avg
-13.89%
5Y Avg
-9.34%
Market Cap
$1.82B
Return on Assets (ROA)
10.25%
TTM Avg
8.68%
3Y Avg
8.17%
5Y Avg
8.38%
Market Cap
$1.89B
Return on Assets (ROA)
-37.11%
TTM Avg
4.34%
3Y Avg
-11.90%
5Y Avg
4.27%
Market Cap
$1.81B
Return on Assets (ROA)
-61.53%
TTM Avg
-47.53%
3Y Avg
-47.53%
5Y Avg
-47.53%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Palvella Therapeutics, Inc. (PVLA) | $1.85B | -24.34% | -44.90% | -10.89% | -12.22% |
| Astrana Health, Inc. (ASTH)vs › | $1.86B | 1.78% | 2.10% | 3.84% | 3.40% |
| Novavax, Inc. (NVAX)vs › | $1.84B | -25.92% | 12.70% | -8.51% | -21.36% |
| Azenta, Inc. (AZTA)vs › | $1.84B | -6.55% | -5.28% | -5.65% | -2.06% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.82B | -4.29% | -7.68% | -13.57% | -14.36% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 11.27% | -4.02% | -13.89% | -9.34% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 10.25% | 8.68% | 8.17% | 8.38% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -37.11% | 4.34% | -11.90% | 4.27% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.81B | -61.53% | -47.53% | -47.53% | -47.53% |
| Novocure Ltd (NVCR)vs › | $1.81B | -18.68% | -15.27% | -14.09% | -9.93% |
ROA
-24.3%
ROE
-28.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -70.04% |
| 2024-12-31 | -19.76% |
| 2023-12-31 | 247.63% |
| 2022-12-31 | -201.39% |
| 2021-12-31 | -29.79% |
| 2020-12-31 | 0.00% |
